City Holding Co. Purchases 2,725 Shares of Amgen Inc. (AMGN)
City Holding Co. raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 21.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,639 shares of the medical research company’s stock after purchasing an additional 2,725 shares during the quarter. Amgen accounts for approximately 0.9% of City Holding Co.’s holdings, making the stock its 28th biggest position. City Holding Co.’s holdings in Amgen were worth $2,693,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its stake in shares of Amgen by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after purchasing an additional 195,200 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Amgen by 1.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock valued at $474,947,000 after purchasing an additional 45,403 shares during the period. UBS Asset Management Americas Inc. grew its stake in shares of Amgen by 3.1% during the 1st quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock valued at $446,250,000 after purchasing an additional 81,362 shares during the period. Swiss National Bank grew its stake in shares of Amgen by 26.5% during the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after purchasing an additional 551,600 shares during the period. Finally, Ameriprise Financial Inc. grew its stake in shares of Amgen by 0.7% during the 1st quarter. Ameriprise Financial Inc. now owns 1,479,687 shares of the medical research company’s stock valued at $242,555,000 after purchasing an additional 10,109 shares during the period. Institutional investors and hedge funds own 78.09% of the company’s stock.
Shares of Amgen Inc. (AMGN) traded down 0.71% during mid-day trading on Friday, hitting $185.32. The stock had a trading volume of 895,263 shares. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. The stock has a market cap of $135.22 billion, a P/E ratio of 16.88 and a beta of 1.35. The firm has a 50 day moving average of $175.99 and a 200-day moving average of $169.31.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.84 earnings per share. Equities research analysts expect that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were given a $1.15 dividend. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.44%. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
A number of research firms have issued reports on AMGN. Royal Bank Of Canada began coverage on Amgen in a research note on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price target for the company. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $203.00 price target on shares of Amgen in a research note on Thursday, September 7th. Cann restated a “buy” rating on shares of Amgen in a research note on Monday, August 28th. Mizuho restated a “buy” rating and set a $183.00 price target (down from $195.00) on shares of Amgen in a research note on Monday, August 21st. Finally, BidaskClub downgraded Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $186.14.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.